Biosecurity Compliance for Independent Researchers: ARPA-H, PAHPA, and the New Rules of Biotech Work

ARPA-H's arrival changes the landscape for independent biotech researchers. Here's what the regulatory framework looks like for scientists working outside large institutional structures.

Assemble Teams Compliance Team ·May 15, 2026 ·1 min read

2022

ARPA-H established by Congress — the most significant new federal biomedical research agency in decades. Its mission: transformative research for health challenges resistant to conventional approaches.

The Advanced Research Projects Agency for Health (ARPA-H) was formally established on May 24, 2022, as the most significant new federal biomedical agency in decades. Modeled on DARPA's high-risk, high-reward research paradigm, ARPA-H is designed to fund transformative health research that the NIH's consensus-driven review process tends to under-fund.

For independent biotech researchers and research organizations working outside large academic medical centers, ARPA-H represents both an opportunity and a new compliance landscape to navigate.

The biosecurity regulatory stack

Research involving dangerous biological agents or select agents — pathogens and toxins that pose the greatest risk to public health and safety — is governed by the Federal Select Agent Program (FSAP), jointly administered by the CDC and USDA. The Public Health Service Act (PHSA) Section 351A and the Agricultural Bioterrorism Protection Act of 2002 form the statutory basis for these requirements.

Key obligations for registered entities: maintain a biosafety plan, inventory and secure all select agents, conduct background investigations on all personnel with access, and report theft, loss, or release within specified timeframes. For independent researchers who handle select agents through institutional affiliation rather than their own registration, understanding which entity holds the FSAP registration is critical.

ARPA-H compliance posture

According to ARPA-H's Strategic Plan for FY 2024-2026, the agency is committed to building proactive health capacity and expanding technical possibilities for health research. Programs include pandemic-preparedness infrastructure and women's health investments. The agency has stated a preference for non-traditional performers — independent researchers, small companies, and organizations not typically participating in the NIH ecosystem.

However, a 2025 GAO report (GAO-25-107418) found that ARPA-H has workforce planning gaps that could affect its ability to manage a portfolio of non-traditional performers effectively. Independent researchers considering ARPA-H engagements should build compliance readiness into their program planning from the start rather than treating it as an afterthought.